Skip to main content
. 2016 Sep 2;6:32734. doi: 10.1038/srep32734

Figure 6. Small molecule inhibitors of SIRT2 decrease G6PD activity and suppress leukaemia cells.

Figure 6

(a–c) HL-60 cells were treated with increasing doses of SIRT2 inhibitors, sirtinol (a), AGK2 (b) and SirReal2 (c), for 6 hours as indicated, G6PD activity was determined. (d–f) HL-60 cells were treated with increasing doses of SIRT2 inhibitors, sirtinol (d), AGK2 (e) and SirReal2 (f), relative cell growth was determined by cell counting after grown for 5 days. (g–i) KG-1 cells were treated with increasing doses of SIRT2 inhibitors, sirtinol (g), AGK2 (h) and SirReal2 (i), for 6 hours as indicated, G6PD activity was determined. (j–l) KG-1 cells were treated with increasing doses of SIRT2 inhibitors, sirtinol (j), AGK2 (k) and SirReal2 (l), relative cell growth was determined by cell counting after grown for 5 days. (m,n) Mouse hematopoietic stem and progenitor cells (HSPC) and RAW264.7 cells were treated with 5 μM AGK2 (m) or 150 nM SirReal2 (n) as indicated and grown for 5 days, cell proliferation curve was determined by cell counting. Error bars represent mean ± SD from three replicates of each sample (**p < 0.01, n.s. = not significant for the indicated comparison).